A groundbreaking advancement in cancer treatment is set to transform the experience for thousands of men in England battling prostate cancer. A new precision radiotherapy technique, known as Stereotactic Ablative Radiotherapy (SABR), reduces the number of treatment sessions from 20 to just five. This development promises to alleviate the physical and emotional burden of prolonged therapy.
How Precision Therapy Changes Treatment
According to a report by the BBC, men in England will now have access to high-powered, precision radiotherapy that slashes their treatment schedule. SABR targets cancerous cells more effectively than standard options while significantly reducing harsh side effects. Although this technology has been used for lung and brain cancers, this marks the first time it will be offered to low- and intermediate-risk prostate cancer patients outside of clinical trials.
Impact on Patients
Approximately 55,000 men are diagnosed with prostate cancer annually in England, with around 17,500 falling into low- or intermediate-risk categories. Experts estimate that about a fifth of these men—roughly 3,500 patients—will opt for this new radiotherapy. Many others choose active monitoring, as low-risk prostate cancers grow slowly and may never cause harm. NHS England expects all 48 of its radiotherapy centers to begin offering the five-session treatment within weeks.
Prof Peter Johnson, National Clinical Director for Cancer, stated, "This technology lets us focus a powerful and precise beam of radiotherapy directly on to the cancer, limiting the damage to healthy cells. The fact it can be delivered in 15 fewer doses will help men get back to living their lives far more quickly."
Charities have also expressed optimism. Amy Rylance from Prostate Cancer UK called it "wonderful news that thousands of men in England will now have access to this revolutionary targeted radiotherapy," noting it will "massively reduce the burden that cancer places on them, and their loved ones." The charity hopes the treatment will expand to more patients in the future.
Trials and Future Prospects
While the current rollout focuses on lower-risk cases, trials are underway to determine if SABR can safely treat high-risk prostate cancer patients. In a related milestone, a Chinese surgeon recently removed a prostate tumor from a patient 220 kilometers away using a robotic surgical system controlled via a high-speed 5G network.
Patient Experience
One trial participant, 70-year-old Edwin Lambert from Suffolk, was diagnosed in January 2025. After initial hormone therapy caused tough side effects like hot flushes, mood swings, fatigue, and loss of libido, he switched to SABR targeting his prostate and lymph nodes. He found it much easier to handle. Lambert observed men undergoing traditional radiotherapy who looked "dreadful" due to repeated treatments. Though he experienced temporary increased urination during and after sessions, he recovered quickly. Within five weeks, he was back on his feet and participating in an archaeological dig. "This treatment was an absolute godsend," he said.
